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Somatic mutations in the mitochondrial genome (mtDNA) have been linked to multiple
disease conditions and to ageing itself. In Drosophila, knock-in of a proofreading deﬁcient
mtDNA polymerase (POLG) generates high levels of somatic point mutations and also small
indels, but surprisingly limited impact on organismal longevity or ﬁtness. Here we describe a
new mtDNA mutator model based on a mitochondrially-targeted cytidine deaminase,
APOBEC1. mito-APOBEC1 acts as a potent mutagen which exclusively induces C:G>T:A
transitions with no indels or mtDNA depletion. In these ﬂies, the presence of multiple non-
synonymous substitutions, even at modest heteroplasmy, disrupts mitochondrial function
and dramatically impacts organismal ﬁtness. A detailed analysis of the mutation proﬁle in the
POLG and mito-APOBEC1 models reveals that mutation type (quality) rather than quantity is a
critical factor in impacting organismal ﬁtness. The speciﬁcity for transition mutations and the
severe phenotypes make mito-APOBEC1 an excellent mtDNA mutator model for ageing
research.
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M itochondria play essential roles in many cellular meta-bolic and signalling processes, most notably in theproduction of molecular energy in the form of ATP and
in the regulation of cell death. Mitochondria also contain their
own genome (mtDNA)—in animals, a circular DNA molecule
that contains 37 genes encoding 13 subunits of the respiratory
chain and ATP synthase, along with the tRNAs and rRNAs
necessary for their production1. As such, the transmission of
germline mtDNA mutations, which occurs exclusively via the
maternal lineage, can give rise to devastating mitochondrial
diseases2,3. Furthermore, since mtDNA exists in multiple copies
per mitochondrion, and thus many copies per cell, this can give
rise to a mixed population of wild-type and mutated genomes, a
condition known as heteroplasmy.
MtDNA has long been considered to be particularly vulnerable
to accumulating spontaneous mutations due to its high replica-
tion rate, proximity to the major source of reactive oxygen species
(the respiratory chain), the absence of protective histones and
limited repair mechanisms4. Consistent with this idea, mtDNA
mutations have been seen to accumulate with age in somatic
tissues in a wide range of organisms including humans, rodents
and invertebrates, and thus have been implicated as a driving
force in the ageing process5,6. Moreover, high levels of mtDNA
mutations have also been found in various age-related conditions
including neurodegenerative disorders such as Parkinson’s and
Alzheimer’s diseases7,8.
To explore the consequences of increasing the level of mtDNA
mutations on cellular and organismal ﬁtness, and the mechan-
isms that counteract such mutations, a number of model systems
have been developed. The best-established model system for
inducing high levels of mtDNA point mutations is via the
expression of a proofreading (exonuclease) deﬁcient variant of the
sole DNA polymerase responsible for replicating mtDNA, POLG.
Mouse strains of this model system exhibit many characteristics
of a premature ageing syndrome, including kyphosis, alopecia,
and osteoporosis, all correlating with a shortened lifespan9,10.
However, the mutational heterogeneity that arises in this model
has led to considerable debate about the pathogenic entity and
whether point mutations are actually driving ageing11–14.
Equivalent ‘mutator’ models have been established in Droso-
phila, either by homologous recombination targeting the endo-
genous locus of the POLG homologue, tamas (tamasexo− ﬂies)15,
or using a genomic transgene bearing a defective tamas16. Recent
studies have shown that mutations that arise in these models have
very limited impact on adult ﬂy health or lifespan16,17, ques-
tioning whether mtDNA mutations are capable of rising to levels
sufﬁcient to impact ageing in ﬂies17.
To circumvent the limitations of the POLG model, we sought
to develop an alternative mtDNA mutator system by employing
the activity of the cytidine deaminase APOBEC1. APOBEC1
(Apolipoprotein B (apoB) mRNA editing catalytic polypeptide 1)
is a vertebrate-speciﬁc, zinc-dependent deaminase which, in
complex with complementing speciﬁcity factor (ACF), catalyses
the deamination of cytosine to uracil (C>U) in apoB mRNA18–20.
Despite a physiological role in mRNA editing, which is fully
dependent upon an RNA-binding accessory subunit, APOBEC1
alone was found to be a potent mutator of DNA both in vitro21
and in vivo22. APOBEC1’s effects as a DNA mutator are
becoming more widely recognised and this ability is being
exploited as a targeting mutagen in combination with zinc-ﬁnger
peptides and CRISPR/Cas923,24. Mechanistically, uracil (U) pre-
sent in DNA is recognised as mutagenic and is usually removed
by uracil-DNA glycosylases, generating an abasic site, which can
itself be inappropriately ﬁlled. However, if uncorrected, in sub-
sequent replication adenine (A) is paired with U to cause a
mutagenic transition of a C:G to U(T):A, resulting in a stable C:
G>T:A point mutation. Importantly, this phenomenon recapitu-
lates the predominant mutation proﬁle in human ageing25. Thus,
we sought to exploit this deaminase activity, directing
APOBEC1 speciﬁcally to mitochondria via a construct we termed
mito-APOBEC1.
In contrast to heterozygous tamasexo− ﬂies, somatic mito-
APOBEC1 expression severely limits mitochondrial function,
organismal vitality and lifespan. A detailed analysis of the
mutation spectra in these models reveals that the mutation proﬁle
(i.e., quality), rather than the overall mutation load (quantity),
correlates with a reduced organismal ﬁtness.
Results
Analysis of tamexo− mtDNA mutagenesis. A Drosophila model
equivalent to the ‘mutator’mouse has been generated by knock-in
of a proofreading (exonuclease) deﬁcient variant of the POLG
homologue, tamas (tamexo−)15. Surprisingly, tamexo− adults have
shown very limited defects on organismal health or lifespan17,
prompting us to examine in greater detail their mutation spectra.
Since the tamexo− strain is homozygous lethal, all our analyses
were conducted on heterozygous animals, inherited either
paternally (+/tamexo−) or maternally (tamexo−/+). Reinsertion
of the wild-type coding region, referred to as tamrescue, served as a
control genotype. As an additional control we also compared the
tam lines to a strain bearing the closest nuclear and mitochon-
drial genetic background; whiteDahomey (wDah) for maternal
inheritance or white1118 (w1118) for paternal inheritance (see
Methods).
Sequence analysis of the tamexo− strains and controls has
previously been performed using a PCR-based cloning and
sequencing strategy15,17. We sought to extend this analysis by
performing Duplex Sequencing of the mitochondrial genome on
individual brains from mutator and control animals (see
‘Methods’ section). Duplex Sequencing is a high-accuracy next-
generation sequencing approach capable of detecting a single
mutation in >107 wild-type bases26. We initially examined the
mtDNA mutation proﬁle of 10-day-old ﬂies to allow for a modest
amount of post-mitotic accumulation of mtDNA mutations. Our
sequencing analysis provided a depth of ~500–1000 unique reads
per site. Although coverage is not uniform across the genome,
patterns of sequencing depth were consistent across all samples
tested, suggesting that no samples bore large deletions within
mtDNA (Supplementary Fig. 1). Sequence analysis identiﬁed
multiple mutations at varying levels of heteroplasmy and several
homoplasmic polymorphisms, depending on the background
strain (Supplementary Data 1). Because we believe high
heteroplasmy mutations could contribute to organismal pheno-
types, we considered a threshold of 70% heteroplasmy (the
maximum we observed) so as to exclude homoplasmic sequence
polymorphisms present in the background parental strain but
capture all other mutations. Hence, for all our analyses we have
included the total number of observed mutations, including
multiple counts for mutations at a same site (heteroplasmy).
Mutation loads were calculated by dividing all mutations by the
total number of nucleotides sequenced, considering the whole or
a subset of the genome, as relevant to each analysis.
The background mtDNA mutation load varied a little by
genotype and individual animal (see Supplementary Data 1),
being 1.5–17 × 10−6 depending on background strain, but
comparable with previous measurements27. The tamrescue con-
trols exhibited similar levels of mtDNA mutations to the
background controls (Supplementary Data 1). In animals with
paternally inherited tamexo−, and hence accumulating only
somatic (and not germline-inherited) mutations, the mtDNA
mutation load increased to 5.7 × 10−5 (Fig. 1a). However, in
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animals with maternally inherited tamexo−, mtDNA mutation
levels were substantially higher (6.9 × 10−4; Fig. 1a). Importantly,
maternally inherited tamexo− ﬂies showed no signiﬁcant altera-
tions in mtDNA copy number (see below). The strong increase in
mutation load of maternally inherited tamexo− is likely a
combination of inherited heteroplasmic mtDNA copies from
the tamexo−-bearing mothers and clonal expansion of replication
errors occurring during the peak mtDNA replication that
happens part-way through embryogenesis28. This is at least
partially supported by the relatively similar number of sites (<2-
fold difference) that are mutated in the paternally and maternally
transmitted mutator ﬂies (Fig. 1b). A much larger mutation load
in a similar number of sites indicates that the same mutated sites
are represented many more times in the maternal tamexo−/+.
These results indicate that zygotically expressed (paternally
inherited) heterozygous tamexo− is not a potent mutator, but
mtDNA mutations can rise to high loads when tamexo− is
maternally inherited. However, maternally inherited tamexo− also
introduces a signiﬁcant number of small insertion/deletion (indel)
mutations (Fig. 1c, and Supplementary Data 2), which can
confound the physiological interpretation of mtDNA point
mutations. Thus, we sought to develop an alternative genetically
encoded mtDNA mutator system with a greater speciﬁcity for
inducing point mutations.
Generation of a new mtDNA mutator model. We generated an
inducible mutator model by exploiting the nucleic acid editing
capability of the cytidine deaminase APOBEC1, which has been
shown to cause C:G>T:A transition mutations in DNA22. Rat
APOBEC1 was cloned into a ‘UAS’ transgenic expression vector
with an N-terminal mitochondrial targeting sequence (MTS)
followed by a hemagglutinin (HA) tag (Fig. 2a). A nuclear export
sequence (NES) was also included to minimise any potential for
nuclear localisation. We termed this construct ‘mito-APOBEC1’.
As a control, we also generated an equivalent construct expressing
a catalytically inactive mutant, E63A (‘mito-APOBEC1E63A’)29.
Independent transgenic lines were established with the constructs
in the same genomic locus to ensure comparable expression levels
and genetic background (Fig. 2b). Subcellular fractionation ana-
lyses determined that mito-APOBEC1 and mito-APOBEC1E63A
were successfully targeted to mitochondria (Fig. 2c); this was
further conﬁrmed by immunoﬂuorescence analysis in larval epi-
dermal cells (Fig. 2d).
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Fig. 1 Maternally inherited tamexo− and mito-APOBEC1 ﬂies generate high mtDNA mutation level. Quantiﬁcation of mtDNA mutations in 10-day-old
paternally inherited tamexo− (+/tamexo−), maternally inherited tamexo− (tamexo−/+) and mito-APOBEC1 mutator ﬂies and respective controls. a mtDNA
mutation load, expressed as number of mutations observed, including heteroplasmic mutations, per total number of bases sequenced [Note that coverage
at the non-coding A+T region, because of its repetitive high A:T content, is minimal and therefore, negligibly contributes to the overall mutation load],
b the number of sites with at least one mutation, c indel mutation load, and d the mutation load identiﬁed by mutation type as indicated. Charts show mean
± SD, n= 3 animals per genotype. Full genotypes are given in Methods. Source data are provided as a Source Data ﬁle and Supplementary Data 1 and 2
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Initial tests determined that the expression of mito-APOBEC1
induced by a range of GAL4 drivers had no gross effects on
development or viability. We chose to conduct the current study
using the ubiquitous driver, da-GAL4. In all instances, transgene
expression was only induced in the zygote, thus avoiding
maternal transmission of germline mutations. Sequence analysis
of mtDNA mutations revealed that zygotic expression of mito-
APOBEC1 is a highly effective mutagen, creating mutation loads
of ~5.5 × 10−4, similar to maternally inherited tamexo−, and
substantially more effective than zygotically expressed, paternally
inherited tamexo− (Fig. 1a and Supplementary Data 1). Interest-
ingly, mito-APOBEC1 mutates a similar number of mitochondrial
genome sites as tamexo− (Fig. 1b). Also, mito-APOBEC1
expression has minimal impact on mtDNA levels (Fig. 3b,d)
and does not affect mtDNA integrity (Fig. 3c, e).
Analysing the mutation proﬁle we found that mito-APOBEC1-
induced changes were almost entirely composed of C:G>T:A
transitions (Fig. 1d, and Supplementary Fig. 2a), consistent with
its mechanism of action. In contrast, although the majority of
tamexo− mutations were also C:G>T:A, a considerable proportion
were T:A>C:G transitions or T:A>A:T transversions (Fig. 1d, and
Supplementary Fig. 2a), as observed in the mouse30. Interestingly,
mapping reciprocal mutations by strand showed a dramatic bias
for mito-APOBEC1, with most of the cytidine deamination events
occurring in the minor strand (G>A transitions in the major
strand) (Supplementary Fig. 3a). This is in line with the strand
pattern and type of mutations naturally occurring in Drosophila
during ageing and across generations27,31. Importantly, in
contrast to maternally inherited tamexo−, mito-APOBEC1 does
not induce small indels (Fig. 1c, and Supplementary Data 2), nor
larger deletions (Fig. 3e). Taken together, these results show that
mito-APOBEC1 is a highly effective, inducible mtDNA mutator
that exclusively causes C:G>T:A transitions at high loads without
causing indel mutations or substantial mtDNA depletion.
The two mutator models affect organismal ﬁtness differently.
We then evaluated the impact of the mutator systems on orga-
nismal ﬁtness. Foremost, with the long-standing association of
mtDNA mutations and ageing, we assessed the effects on lifespan.
In agreement with recent ﬁndings17, we found that both pater-
nally and maternally inherited tamexo− showed minimal impact
on lifespan (Fig. 4a, c). In stark contrast, expression of mito-
APOBEC1 caused a dramatic reduction in median and maximal
lifespan (Fig. 4e).
This striking difference in lifespan led us to investigate whether
there was a similar differential effect on vitality during ageing as
an indicator of ‘healthspan’. Locomotor assays, such as startle-
induced negative geotaxis (climbing), offer a sensitive and reliable
read-out of the neuromuscular circuit function. Analysing the
climbing ability of the tamas mutator lines, either paternally or
maternally inherited, we found no difference between any of the
genotypes in 2-, 10- and 30-day-old ﬂies (Fig. 4b, d). However,
consistent with the effects on lifespan, expression of
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mito-APOBEC1 caused a signiﬁcant reduction in climbing ability
across all ages tested (Fig. 4f).
Given the strong phenotypic effects of mito-APOBEC1 but not
tamexo−, we sought to address potentially unrecognised extra-
mitochondrial effects of this construct. To this end, we generated
transgenic lines expressing HA-tagged wild-type and mutant
APOBEC1 variants lacking the MTS but retaining the NES
sequences (Supplementary Fig. 4a), which we termed ‘cyto-
APOBEC1’ and ‘cyto-APOBEC1E63A’. The cyto-APOBEC1 lines
appear to express the transgene at higher level than mito-
APOBEC1 lines, in comparison tomito-HA-GFP (compare Fig. 2b
with Supplementary Fig. 4b); yet encouragingly, we observed no
effect of cyto-APOBEC1 expression upon lifespan or locomotor
ability with age (Supplementary Fig. 4c, d). Thus, there appears to
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be no detrimental effects of cyto-APOBEC1, substantiating the
idea that the impact of mito-APOBEC1 expression on organismal
ﬁtness derives exclusively from mtDNA mutations.
mito-APOBEC1 but not tamexo− affects mitochondrial func-
tion. Having established the relative impact of the mutator models
on organismal ﬁtness, we next sought to understand the impact on
mitochondrial function. We ﬁrst assessed the oxygen consump-
tion rate (OCR) using high-resolution respirometry. Analysing the
maternally inherited tamexo− heterozygotes we found no sig-
niﬁcant change to either Complex I- or Complex II-linked
respiration, even after substantial ageing (Fig. 5a). In contrast,
mito-APOBEC1 expressing ﬂies showed a signiﬁcant decrease in
Complex I-linked respiration, already in very young ﬂies (Fig. 5b).
Although the downturn in Complex II-linked respiration did not
reach signiﬁcance at 2 days, by 10 days old this too was sig-
niﬁcantly reduced (Fig. 5b). Because Complex-II is exclusively
composed by nuclear-encoded proteins, we hypothesized the
defect was due to dysfunctional Complex-III and/or IV. Con-
sistent with these ﬁndings, BN-PAGE and in-gel activity assays
showed a decrease in Complex-I and Complex-IV activity, while
Complex-II activity was undiminished, even possibly increased
(Fig. 5c). Assessing the steady-state levels of the assembled com-
plexes by native-PAGE immunoblotting we found that mito-
APOBEC1 ﬂies consistently displayed decreased amounts of
higher-order assemblies of Complexes I, III, IV and V (Fig. 5d),
with partial accumulation of non-functional intermediates.
MtDNA mutations could potentially also impact transcription,
causing a decline in transcript levels. To assess this, we analysed
several transcripts from the mitochondrial genome by quantita-
tive RT-PCR. Expression of the catalytically dead mito-
APOBEC1E63A resulted in a moderate but signiﬁcant reduction
of all mitochondrial transcripts analysed (Fig. 3f), which mirrored
the lowered amounts of mtDNA copies in these ﬂies (Fig. 3b, d).
In contrast, transcript levels in mito-APOBEC1 ﬂies were
comparable or slightly higher than controls (Fig. 3f). Taken
together, these data indicate that mito-APOBEC1-induced muta-
tions compromise OXPHOS assembly and respiration likely by
the cumulative impact on mitochondrial-encoded OXPHOS
components.
Analysis of the mtDNA mutation proﬁles. An unexpected
ﬁnding from our work concerns the similar mutation loads found
in maternal tamexo− and mito-APOBEC1 ﬂies, but the strikingly
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lifespan, statistical signiﬁcance was determined by Log-rank (Mantel–Cox) test; the number of animals tested are indicated in the legend. For locomotor
assays, charts show mean ± 95% conﬁdence interval. The number of animals tested are shown per column. Statistical signiﬁcance was determined by
Kruskal–Wallis nonparametric test with Dunn’s multiple comparisons correction. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. All other comparisons
are non-signiﬁcant but are not indicated to aid clarity. Source data are provided as a Source Data ﬁle
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different organismal consequences of those mutations. This
suggests that the amount of mtDNA mutations alone is not
sufﬁcient to explain the difference in pathogenicity. Therefore, we
undertook a deeper analysis of the mtDNA mutation proﬁle
observed in the two mutator systems.
We ﬁrst assessed the degree to which the observed mutations
may have undergone clonal expansion. Mutations that occur at
less than 1% heteroplasmy are generally considered to represent
recently acquired or de novo mutational events, while mutations
present at higher than 1% heteroplasmy are thought to have
expanded clonally through replication of an initial event. We
compared the overall mutation load, up to 70% heteroplasmy,
with that found at less than 1% heteroplasmy (Fig. 6a–c, and
Supplementary Data 1). Paternally inherited tamexo− ﬂies showed
very little difference in mutation load between <1% and <70%
heteroplasmy (Fig. 6a), consistent with these mutations being
recently acquired. Indeed, only a few sites in paternally inherited
tamexo− ﬂies showed >1% heteroplasmy (Fig. 6d, Supplementary
Fig. 1b). In contrast, a substantial proportion of mutations in
mito-APOBEC1 and maternally inherited tamexo− occurred at
higher than 1% heteroplasmy (Fig. 6b, c, and Supplementary
Fig. 1b). Notably, 23% of all mutated sites in mito-APOBEC1
(Fig. 6d) displayed a moderate level of heteroplasmy (mainly
between 1–10% heteroplasmy, Fig. 6f), while in tamexo−/+ a
smaller proportion of clonally mutated sites (13% of all mutated
sites, Fig. 6d) distributed as a few moderately heteroplasmic
positions together with a handful of high clonally (>30%
heteroplasmy) mutated sites (Fig. 6e).
Since the preceding mutation analyses were performed on 10-
day-old ﬂies, we wanted to determine the extent to which these
mutations were present in early adulthood, in 2-day-old ﬂies
(Supplementary Data 3). Mutation loads were similar between 2-
and 10-day-old ﬂies across all genotypes tested (Supplementary
Fig. 5a). However, while a similar number of sites were mutated
in mito-APOBEC1 ﬂies at 2 and 10 days, the number of mutated
sites approximately doubled in both tamexo− conditions (Supple-
mentary Fig. 5b). Therefore, during this short time frame, tamexo−
was able to introduce mutations at additional genomic positions,
consistent with reports that mtDNA replication indeed occurs in
adult ﬂy tissues27. In contrast, the lack of increase in mito-
APOBEC1-targeted sites suggests the mutable positions may have
already been saturated by 2 days. Consistent with this, comparing
the heteroplasmy proﬁle of 2- and 10-day-old tamexo− ﬂies
showed no appreciable increase in the number of clonally
mutated sites (1–70% heteroplasmy) while the number of sites
with de novo mutations (<1% heteroplasmy) speciﬁcally
increased (Supplementary Fig. 5b). It should be noted that the
additional mutations at <1% heteroplasmy in 10-day-old ﬂies are
numerically very small compared to the large number of
mutations present at higher (1–70%) heteroplasmy, accounting
for why the overall point mutation load does not signiﬁcantly
increase with age. As above, the heteroplasmy proﬁle of mito-
APOBEC1-targeted sites did not change between 2 and 10 days
(Supplementary Fig. 5b).
Being unable to ascribe the divergent organismal outcome of
tamexo− and mito-APOBEC1 ﬂies to difference in their hetero-
plasmy proﬁle, we next considered whether the topography of the
mutations may offer some explanation as to the different
pathogenicity. In all three mutator models, point mutations were
widely distributed across the mtDNA genome (Supplementary
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Fig. 1), with no particular bias towards any particular region or
genomic feature; protein coding, tRNA, rRNA or non-coding
(Supplementary Fig. 2b). Focussing on the protein-coding genes,
we calculated the ratio of non-synonymous to synonymous (NS:
S) mutations found in each genotype (Supplementary Fig. 6a).
Non-synonymous mutations in either of the tamexo− mutator
lines essentially exist as recent or de novo events (<1%
heteroplasmy, Fig. 7a), and the NS:S ratio in these lines is low
(Fig. 7b) and similar to the ratio found in controls (Supplemen-
tary Fig. 6a). In contrast, mito-APOBEC1 produced a high
number of NS mutations, particularly at sites with >1%
heteroplasmy (Fig. 7a), resulting in a dramatic increase in the
NS:S ratio (Fig. 7b).
Several characteristics of the mutation proﬁle likely contribute
to this difference between the tamexo− and mito-APOBEC1
mutators. First, considering that mito-APOBEC1 exclusively
targets C:G nucleotides (Supplementary Fig. 2a), it is notable
that C:Gs are predominantly found in protein-coding regions
(Supplementary Fig. 6b), particularly in the critical ﬁrst and
second codon-base positions (Supplementary Fig. 6c). Indeed,
mito-APOBEC1 disproportionately (~98% of all recovered
mutations) mutates the ﬁrst or second codon-base position
(Supplementary Fig. 6d). Consistent with tamexo− creating a
greater diversity of substitutions (Supplementary Fig. 2a), a
substantial portion (21%) of tamexo−-induced mutations affects
nucleotides at the third position in the codon (Supplementary
Fig. 6d), sites that tend to be degenerate (mutations lead to
synonymous substitutions). Second, mito-APOBEC1 is highly
selective for targeting deamination of cytidine in a TCn context,
particularly in the TCT trinucleotide sequence (Supplementary
Fig. 7), as previously reported32. Therefore, mito-APOBEC1-
induced mutations are restricted to fewer sites in the genome,
which may expand to higher heteroplasmy due to multiple,
independent targeting events. In contrast, similar to the codon
position analysis, tamexo−mutators show much less selectivity for
the surrounding nucleotide context (Supplementary Fig. 7).
Third, a signiﬁcant proportion of tamexo−-induced mutations
are T>C substitutions, which are much more likely to result in a
synonymous change (Supplementary Fig. 6e). Taken together,
these data demonstrate that mito-APOBEC1 induces predomi-
nantly non-synonymous mutations.
As a further estimate of the pathogenicity of the mutations that
each model introduces at protein-coding genes, we calculated the
MutPred pathogenicity score (see ‘Methods’ section) for every
mutated site recovered in each of our mutator genotypes at
10 days old. All three mutators show a similar MutPred score
distribution when considering sites at <1% heteroplasmy, with
either of tamexo− mutators having a substantial abundance of
synonymous (0-scored) sites (Fig. 7c). However, higher hetero-
plasmy sites (1–70%) in mito-APOBEC1 show a strong
preponderance for elevated MutPred scores (Fig. 7d). As for
<1% heteroplasmy sites, a substantial proportion of the 1–70%
heteroplasmy positions in tamexo−/+ are synonymous and
therefore non-pathogenic (Fig. 7d).
Taken together, these analyses indicate that the high selectivity
of mito-APOBEC1 for C:G>T:A transitions generates a remark-
ably high proportion of non-synonymous and potentially
pathogenic mutations which, despite achieving only moderate
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heteroplasmy, confer a strongly detrimental effect on mitochon-
dria. The different pathogenicity of the mutations introduced by
mito-APOBEC1 or tamas mutators offers a plausible explanation
for the striking differences on organismal lifespan and vitality
between the two models.
Discussion
The accumulation of mtDNA mutations has been implicated in
various age-related pathologies and in the ageing process itself5,6.
The POLG-based mutator systems, which display a striking
progeroid syndrome in mice9,10, have emerged as the pre-
dominant model for obtaining high levels of stochastic mtDNA
mutations. However, the mutational heterogeneity that arises in
this model, which includes point mutations as well as small
indels, large deletions, and mtDNA depletion, has led to con-
siderable debate about the pathogenic entity and whether point
mutations are actually driving ageing11–14. Recently described ﬂy
and worm POLG mtDNA mutators, which offer an attractive
system for their powerful genetic approaches, also show evidence
of this mutational heterogeneity15,16,33. However, while the ﬁrst
ﬂy model equivalent to the POLG-mutator was homozygous
lethal15, a similar model recently reported is not lethal16, raising
uncertainty about the cause of the lethality. To establish a ‘clea-
ner’ mutator system we have developed an alternative mutator
model, mito-APOBEC1, which we showed is a potent mtDNA
mutagen that exclusively induces high levels of C:G > T:A tran-
sition mutations, in the absence of indels or mtDNA depletion.
Because we believe the level of heteroplasmy will contribute to
the pathogenicity of a mutation proﬁle, the mutation loads cal-
culated here reﬂect the overall amount of mutations we recovered,
including multiple events at a same site. This clonality is generally
assumed to be due to clonal propagation of an initial mutational
event via replication. However, it is also possible that the same
mutational event can independently occur in different molecules,
in an iterative mechanism that is independent of mtDNA repli-
cation. This is particularly relevant for our mito-APOBEC1
model which has a very high degree of sequence selectivity and is
not directly linked to replication unlike a polymerase-based
(tamexo−) model.
Comparing the POLG/tamas and mito-APOBEC1 model sys-
tems, we ﬁnd that although a similarly high mtDNA mutation
load can arise in both mito-APOBEC1 and maternally inherited
tamexo− ﬂies, they cause dramatically different effects on orga-
nismal ﬁtness. While mutations generated by mito-APOBEC1
lead to profound shortening of lifespan and loss of vitality
(Fig. 4e, f), associated with a broad spectrum of mitochondrial
impairments (Fig. 5b–d), tamexo− does not provoke any major
defects either at the organelle or organismal level (Figs. 4a–d and
5a).
The in-depth mutation analysis method we used allowed us to
gain a detailed view of the mutation proﬁles in these models.
First, there is a striking difference (> 10-fold) in the overall
mutation load when tamexo− is inherited paternally versus
maternally (Fig. 1a). This is accounted for by a number of clonally
expanded mutations (Fig. 6a, b, d, e) which likely arise through
replication of germline transmitted mutations or very early
mutagenesis by maternally deposited Tamexo− protein, which is
abundant enough to allow tam mutants to development to the
third instar stage34. The increase in de novo but not clonally
mutated sites between 2- and 10-day-old tamexo− ﬂies (Supple-
mentary Fig. 5b) further supports that mtDNA continues to
undergo replication in adults27, but that clonal expansion events
likely occur only in development, probably during the peak of
mtDNA replication part-way through embryogenesis28. Inter-
estingly, mito-APOBEC1, which is only expressed in the zygote
and not maternally transmitted, also produces a substantial
amount of highly heteroplasmic sites (Fig. 6c), in stark contrast to
paternally inherited (zygotically expressed) tamexo− (Fig. 6a).
mito-APOBEC1-induced mutations could expand to high het-
eroplasmy through replication but also via iterative targeting of
cytidines on different mtDNA molecules. Further work will be
needed to determine the mechanistic basis for this phenomenon,
but we hypothesise that, since APOBEC1 is known to bind single-
stranded DNA20, mutations may occur during transcription in
addition to during replication, as it has previously been sug-
gested32. Remarkably, the mutation load, number of mutated sites
and degree of heteroplasmy did not change in the mito-APOBEC1
ﬂies between 2 and 10 days (Supplementary Fig. 5). We hypo-
thesise that mito-APOBEC1 is such an efﬁcient mutator that the
mutable sites compatible with life are saturated early in devel-
opment. Further insight into these mechanisms could be gained
from analysing the changes in mutation proﬁle during develop-
mental stages in these models. Similarly, it will also be informa-
tive to explore which, if any, additional changes occur during a
more substantial period of ageing.
Eliminating differences in heteroplasmy levels as a mechanistic
explanation for the differing organismal phenotypes between
tamexo− and mito-APOBEC1, we focused our analyses on the
mutation proﬁle. While both models show a predisposition to
create C:G>T:A mutations (Fig. 1d and Supplementary Fig. 2a),
mito-APOBEC1 leads to a higher proportion of potentially
damaging mutations and non-synonymous substitutions (Fig. 7).
The increased pathogenicity of the mito-APOBEC1 spectrum is
likely caused by its exclusive targeting of C:G nucleotides (Sup-
plementary Fig. 2a), particularly in a TCn context (Supplemen-
tary Fig. 7), while tamexo− has a more variable spectrum of
substitutions, including transversions (Supplementary Fig. 2a),
and a less stringent neighbouring sequence requirement (Sup-
plementary Fig. 7). Notably, Drosophila mtDNA has evolved to
have an unusually low C:G content (Supplementary Fig. 6b),
likely retaining them predominantly at critical sites (Supple-
mentary Fig. 6c); thus, C:G mutations are presumably more likely
to be damaging31,35. Consequently, we surmise that mtDNA
mutation type (quality) rather than quantity is a critical factor in
impacting organismal ﬁtness. One limitation of our work is that
we have restricted our sequence analyses predominantly to
protein-coding sequence. Future work will determine whether the
context speciﬁcity of mito-APOBEC1 also leads to an enrichment
of pathogenic mutations within tRNA and rRNA sequences, and
how these may impact organismal ﬁtness and ageing.
The fact that mito-APOBEC1 ﬂies show such detrimental
phenotypes but only modest levels of heteroplasmy is also intri-
guing. Typically, for mitochondrial diseases resulting from
mtDNA mutations, heteroplasmy levels must rise above a certain
threshold (>60–90%), to cause mitochondrial functional
impairment36,37. This phenomenon is also replicated in a number
of Drosophila strains with homoplasmic mtDNA mutations that
present strong mitochondrial and neuromuscular defects38–40.
However, a threshold level can be reached not only by one spe-
ciﬁc mutation but by the sum of a number of different muta-
tions14. Our results from mito-APOBEC1 ﬂies support this view.
Mutations can produce cumulative defects on the same protein or
multi-protein complexes that limit the possibility of com-
plementation. Alternatively, mutations can arise locally to very
high heteroplasmy and create a mosaic of affected cells within a
tissue. Current sequencing technologies, however, cannot distin-
guish between these scenarios and would appear as apparent
lower level heteroplasmy on aggregate. Such a death-by-a-thou-
sand-cuts model could help explaining how the variety of
mtDNA mutations frequently observed in ageing and in a
number of neurodegenerative diseases could have a phenotypic
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effect without ever reaching the high level of heteroplasmy typi-
cally associated with mitochondrial diseases25,41–43.
Finally, we posit that the mito-APOBEC1 model circumvents
several limitations of the existing POLG-based mutator models
and offers several advantages. First, it allows us to speciﬁcally
address the impact of point mutations, in the absence of indels or
mtDNA depletion. Second, the stronger phenotypes induced in
this model provide an opportunity to screen for genetic modiﬁers
to identify factors inﬂuencing the pathogenicity of mtDNA
mutations. Third, as mito-APOBEC1 is based on the classic
GAL4/UAS transgenic approach this opens it up to the full power
and versatility of Drosophila genetics, providing an unparalleled
toolbox for a range of spatial and temporal manipulation, such as
tissue-speciﬁc or life course-speciﬁc expression. Beyond Droso-
phila, this study acts as a proof-of-principle to extend the indu-
cible mito-APOBEC1 model system to other organisms where it
would provide analogous advantages over existing mutator
models to further decipher the pathophysiology of mtDNA
mutations.
Methods
Drosophila stocks and husbandry. Flies were raised under standard conditions in
a humidiﬁed, temperature-controlled incubator with a 12 h:12 h light:dark cycle at
25 °C, on food consisting of agar, cornmeal, molasses, propionic acid and yeast.
Transgene expression was induced using the ubiquitous da-GAL4 driver. The
following strains were obtained from the Bloomington Drosophila Stock Center
(Bloomington Drosophila Stock Center, RRID:SCR_006457): w1118 (RRID:
BDSC_6326), da-GAL4 (RRID:BDSC_55850), UAS-mito-HA-GFP (RRID:
BDSC_8443). wDah (w- [Dahomey, Wolbachia-free]), tamexo− and tamrescue ﬂies
were a gift from N-G. Larsson (Max Planck Institute for Ageing, Cologne). Unless
otherwise stated, all experiments were conducted using male ﬂies.
Genotypes used in this study
Group Label Genotype
Paternal tamas control w1118;+ /+
+/tamrescue w1118;+ /TI{TI}tamRescue
+/tamexo− w1118;+/ TI{TI}tamD263A
Maternal tamas control wDah;+ /+
tamrescue /+ wDah; TI{TI}tamRescue/+
tamexo−/+ wDah; TI{TI}tamD263A/+
mito-
APOBEC1
control w1118; P{UAS-mito-HA-GFP}/+; P{da-GAL4}/
+
mito-
APOBEC1E63A
w1118; P{UAS-mito-HA-APOBEC1E63A}/+; P
{da-GAL4}/+
mito-APOBEC1 w1118; P{UAS-mito-HA-APOBEC1}/+; P{da-
GAL4}/+
Generation of APOBEC1 transgenic lines. mito-APOBEC1 fusion constructs were
made by fusing the MTS of human ATP synthase subunit F1β (ATP5F1B), a
haemagglutinin (HA) epitope and a ﬂexible linker sequence 5′ to the rat APOBEC1
cDNA which lacked the initial ATG and stop codon. A nuclear exporting sequence
(NES) was inserted 3′ to APOBEC1. The Glu63Ala (APOBEC1E63A) catalytically
dead mutant was created by changing the codon GAA to GCT at amino acid
position 63 of the cDNA by site-directed mutagenesis. Mitochondria-excluded,
cytoplasmic versions of APOBEC1 constructs (cyto-APOBEC1) were generated by
removing the MTS sequence from the mito-APOBEC1 transgenes. Engineered
sequences were cloned into the pUASTattB vector and injected in Drosophila
embryos for phiC31-mediated transgenesis at the attP40 site (BestGene, RRID:
SCR_012605).
DNA isolation for sequencing. Brains from individual male ﬂies of the indicated
age were dissected in PBS, ﬂash frozen in dry ice, and stored at −80 °C. Total DNA
was isolated from individual brains using the QIAamp DNA Micro isolation kit
following the manufacturer’s instructions (QIAGEN, RRID:SCR_008539). DNA
yield for a single brain typically ranged between 20–30 ng.
Duplex sequencing and mutation calling. DNA was prepared for Duplex
sequencing using a previously described protocol44 with several modiﬁcations.
Brieﬂy, ~20 ng of total DNA was sonicated in 60 μL of nuclease-free ddH2O using a
Covaris AFA system with a duty cycle of 10%, intensity of 5, cycles/burst 100, time
20 s × 5, temperature of 4 °C. After sonication, each sample was subjected to end-
repair and 3′-dA-tailing using the NEBNext Ultra End-repair/dA-tailing kit (New
England Biolabs, RRID:SCR_013517) according to the manufacturer’s instructions.
Each sample was then ligated with 2 μL of 15 μM Duplex Sequencing adapters,
using the NEBNext Ultra Ligation kit (New England Biolabs, RRID:SCR_013517)
according to the manufacturer’s instructions. Duplex Sequencing adapters used in
collecting data for analysing mutation-selection were chemically synthesized as a
collaborative effort with Integrated DNA Technologies to develop a prototype
synthesis method. Each sample was then cleaned of excess adapters using Agen-
Court AmpureXP magnetic beads, and PCR ampliﬁed44. The mitochondrial DNA
was isolated by targeted DNA capture using IDT xGen Lockdown probes (Inte-
grated DNA Technologies OligoAnalyzer, RRID:SCR_001363) speciﬁc for non-
repeat regions of the Drosophila mitochondrial genome, using the manufacturer’s
instructions.
The captured DNA samples were sequenced on an Illumina NextSeq500 using
150 bp paired-end sequencing. The resulting reads were aligned against the
Drosophila genome (BDGP Release 6+ ISO1 MT/dm6) using the Burrows-
Wheeler Aligner (BWA, RRID:SCR_010910) and Samtools45 (SAMTOOLS, RRID:
SCR_002105) coupled with a custom software workﬂow44. Reads not uniquely
mapping to the mitochondrial genome were excluded from further analysis. The
non-coding A+T region [ChrM:14917-19524] has a repetitive high A:T content
(~95%) which confounds sequence capture and mapping. The majority of A+T
region is therefore not included in the calculation of mutation load (see
Supplementary Data ﬁles for full details). After processing, we called de novo
mutations by using a cut-off that excluded variants occurring at > 1%
heteroplasmy, while global mutation loads included all mutations with
heteroplasmy <70% at each position.
mtDNA mutation analysis. For each animal, point mutation or indel loads were
calculated as the total number of mutations, insertions or deletions per total
number of nucleotides sequenced, considering the whole or a subset of the genome,
as relevant to each analysis. Full details of sequencing results and mutations per
animal are shown in Supplementary Data ﬁles. For heteroplasmy distribution
analysis, results from individual ﬂies per genotype were aggregated.
The trinucleotide context of mutations was calculated using previously
published pipelines on the aggregated sequence data from ﬂies of the same
genotype16,46. Each mutation was characterized according to both the identity of
the mutation as well as the nucleotides 3′ and 5′ of the mutation site, and binned
into one of the 96 total possible mutation types. To calculate the load of mutations
in each trinucleotide context, we ﬁrst determined the total genome-wide post-
processing duplex depth for each of the 16 total trinucleotide contexts. We then
calculated the trinucleotide mutation load for each of the 96 mutation types by
dividing the total number of mutations for each mutation type by its post-
processing duplex depth.
Calculations for the distribution of mutation positions, trinucleotide context
and mutation loads throughout the genome were calculated using Microsoft Excel
for Mac v.16 (Microsoft Excel, RRID:SCR_016137) and scripts developed in
Python 2.7 or Python 3.6 (Python Programming Language, RRID:SCR_008394).
Graphs were generated using GraphPad Prism software (GraphPad Prism, RRID:
SCR_002798) or R software (R Project for Statistical Computing, RRID:
SCR_001905).
The MutPred software (MutPred, RRID:SCR_010778)47 was used to calculate
pathogenicity scores for all non-synonymous (NS) variants detected in mutator
ﬂies. In addition, we assigned a score of 0 to all non-synonymous changes, and a
score of 1 to nonsense mutations or mutations changing a stop codon to coding.
MutPred scores for all detected single nucleotide changes were aggregated by
genotype and plotted as a frequency distribution.
mtDNA copy number. Total DNA was extracted from 10–20 male ﬂies using the
DNeasy Blood and Tissue kit (Qiagen) and following manufacturer’s instructions.
Quantiﬁcation of mtDNA was performed in triplicate by multiplex TaqMan qPCR
ampliﬁcation of the mitochondrial genes mt:CoI and mt:lrRNA, and the nuclear
gene RpL32 as normalizing reference. The following primers were used: (mt:CoI)
5′-TTCTACCTCCTGCTCTTTCTTTAC and 5′-CAGCGGATAGAGGTGGA-
TAAAC, probe 5′-FAM-AATGGAGCTGGGACAGGATGAACT-TAMRA; (mt:
lrRNA) 5′-AGATAGAAACCAACCTGGCTTAC and 5′-
TTGGGTGTAGCCGTTCAAAT, probe 5′-FAM-ACCGGTTTGAACTCAGA
TCATGTAAGA-TAMRA; (RpL32) 5′-CACCGGAAACTCAATGGATACT and
5′-CACACAAGGTGTCCCACTAAT, probe 5′-FAM-CCAAGAAGC
TAGCCCAACCTGGTT-TAMRA. PCR reactions were performed according to
standard conditions for TaqMan (Applied Biosystems, RRID:SCR_005039): 50 °C
for 2 min; 95 °C for 10 min; 40 cycles at 95 °C 15 s, 60 °C 1min. The expression of
mtDNA copy number relative to nuclear DNA was determined using the 2−ΔΔCT
method. The relative quantiﬁcation was corrected for PCR efﬁciency of each
primer pair.
Southern blot. Total DNA was extracted from 150–180 7-day old ﬂies using
phenol:chloroform following the protocol in the VDRC website (Vienna Droso-
phila Stock Center, RRID:SCR_013805) (https://stockcenter.vdrc.at/images/
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downloads/GoodQualityGenomicDNA.pdf). 5 ug of DNA was digested with PstI
(New England Biolabs, RRID:SCR_013517) according to manufacturer’s instruc-
tions, and resolved on a 0.55% agarose gel. Blotting, labelling of probe DNA and
membrane hybridisation were performed using standard procedures48. Membranes
were exposed to a storage phosphor screen for 24–96 h before imaging with an
Amersham Typhoon RGB scanner and processing with ImageQuant software
(ImageQuant, RRID:SCR_014246). Probe primer sequences were as follows: (mt:
CoII—3276–3840) 5′-AACTATTTTACCAGCAATTATTTTACT and 5′-CAGTC
ATCTAATGAAGAGTTATTTCTA; (18S rDNA) 5′-CGATGCCAGCTAGCAA
TTGGGTGTAG and 5′-CTACACCCAATTGCTAGCTGG.
Long-range PCR. Total DNA was extracted from 10–20 male ﬂies using the
DNeasy Blood and Tissue kit (Qiagen) and following manufacturer’s instructions.
PCR ampliﬁcation was performed using PrimeSTAR GXL DNA Polymerase under
manufacturer’s conditions (Clontech, RRID:SCR_004423), with 1 μM of primers
and the following ampliﬁcation conditions: 94 °C, 1 min; 98 °C, 30 s; 68 °C, 13 min
(30 cycles); 72 °C, 10 min. Primers used (14.2F: 5′-GCCGCTCCTTTCCATT
TTTGATTTCC and 14.2R: 5′-TGCCAGCAGTCGCGGTTATACCA) amplify a
product encompassing almost the complete mtDNA molecule. The PCR products
were then visualized after electrophoresis on 0.8% agarose and 2X Invitrogen SYBR
Safe DNA Gel Stain (Thermo Fisher Scientiﬁc, RRID:SCR_008452) and 1 kb DNA
Ladder (New England Biolabs, RRID:SCR_013517).
qRT-PCR of mtDNA transcripts. Total RNA was extracted from 10 7-days old
male ﬂies using the Direct-zol MiniPrep kit (Zymo Research, RRID:SCR_008968).
Genomic DNA contamination was removed from RNA using Turbo DNAse
(Ambion Inc, RRID:SCR_008406), according to manufacturer’s protocol. cDNAs
were generated from 80 ng of total RNA using the Maxima H Minus cDNA
Synthesis Master Mix with dsDNAse (Thermo Fisher Scientiﬁc, RRID:
SCR_008452), following manufacturer’s instructions. To ensure that RNA had no
genomic DNA contamination, a control reaction was included in which no reverse
transcription was carried out. Reactions were carried out using a QuantStudio 3
Real-Time PCR Systems (Thermo Fisher Scientiﬁc, RRID:SCR_008452) with
Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientiﬁc, RRID:
SCR_008452). Primers were as follows: (mt:CoI) 5′-CAGGATGAACTGTTT
ATCCACCTTT and 5′-AATCCCTGCTAAATGTAGAGAAAAAATAG; (mt:
ND3) 5′-AAAAAGCTTTAATCGACCGAGA and 5′-CGTAAAGAA
AATGGTAATCGAGATG; (mt:CytB) 5′-AAATTTATTGGGAGACCCTGATA
AC and 5′-GGAATAGATCGTAAAATAGCATAAGCA; (mt:ND4) 5′-AACCC
AGAAGAACATAAACCA and 5′-TGCTTATTCATCTGTTGCTCA; (mt:lrRNA)
5′-ACCTGGCTTACACCGGTTT and 5′-GGGTGTAGCCGTTCAAATTT;
(RpL32) 5′-AAACGCGGTTCTGCATGAG and 5′-GCCGCTTCAAGGGAC
AGTATCTG; (Tub84b) 5′-TGGGCCCGTCTGGACCACAA and 5′-TCG
CCGTCACCGGAGTCCAT. Primers’ speciﬁcity was assessed by melting curve
proﬁle and their efﬁciency ranged from 0.92 to 0.99. Mitochondrial transcripts
levels were normalised to a geometric mean of both Rpl32 and Tub84b reference
genes, using the comparative Ct method. The relative quantiﬁcation was corrected
for PCR efﬁciency of each primer’s couple.
Locomotor and lifespan assays. The startle induced negative geotaxis (climbing)
assay was performed using a counter-current apparatus. Brieﬂy, 20–23 males were
placed into the ﬁrst chamber, tapped to the bottom, and given 10 s to climb a 10 cm
distance. This procedure was repeated ﬁve times (ﬁve chambers), and the number
of ﬂies that has remained into each chamber counted. The weighted performance
of several group of ﬂies for each genotype was normalized to the maximum pos-
sible score and expressed as Climbing index49.
For lifespan experiments, ﬂies were grown under identical conditions at low-
density. Progeny were collected under very light anaesthesia and kept in tubes of
approximately 25 males each. Flies were transferred every 2–3 days to fresh
medium and the number of dead ﬂies recorded. Percent survival was calculated at
the end of the experiment after correcting for any accidental loss.
Immunoﬂuorescence experiments. For APOBEC1 immunostaining, larval epi-
dermis was dissected in PBS and ﬁxed in 4% formaldehyde for 30 min at RT,
followed by permeabilization in 0.3% Triton X-100 for 30 min and blocking with
0.3% Triton X-100, 1% BSA in PBS for 1 h at RT. Tissues were incubated with anti-
HA and anti-ATP5A antibodies diluted in blocking buffer overnight at 4 °C, and
with the appropriate ﬂuorescent secondary antibodies for 2 h at RT. Samples were
washed several times in PBS and mounted on slides using Prolong Diamond
Antifade mounting medium (Thermo Fisher Scientiﬁc, RRID:SCR_008452).
Microscopy. Confocal imaging was conducted using a Zeiss LSM 880 microscope
(Carl Zeiss MicroImaging) equipped with Nikon Plan-Apochromat 63 × /1.4 NA
oil immersion objective. Images were prepared using Fiji software (Fiji, RRID:
SCR_002285).
Respirometry. Mitochondrial respiration was assayed at 30 °C by high-resolution
respirometry using a Oxygraph-2k high-resolution respirometer (OROBOROS
Instruments) using a chamber volume set to 2 mL. Calibration with the air-
saturated medium was performed daily. Data acquisition and analysis were carried
out using Datlab software (OROBOROS Instruments). Five ﬂies per genotype were
homogenised in Respiration Buffer [120 mM sucrose, 50 mM KCl, 20 mM
Tris–HCl, 4 mM KH2PO4, 2 mM MgCl2, and 1 mM EGTA, 1 g L−1 fatty acid-free
BSA, pH 7.2]. For coupled (state 3) assays, complex I-linked respiration was
measured at saturating concentrations of malate (2 mM), glutamate (10 mM) and
adenosine diphosphate (ADP, 2.5 mM). Complex II-linked respiration was assayed
in Respiration Buffer supplemented with 0.15 µM rotenone, 10 mM succinate and
2.5 mM ADP. The addition of proline to the respiration buffer can increase
respiration rate in insect samples but was not included here. Respiration was
expressed as oxygen consumed per ﬂy. Flies’ weight was equal in all genotypes
tested.
Biochemical assays. Mito-APOBEC1 ﬂies and controls were aged to 10–12 days
before collection for mitochondria isolation. 1 mL of ﬂies per genotype were
homogenised in 2 mL of STE buffer [250 mM Sucrose, 5 mM Tris, 2 mM EGTA,
pH 7.4]+ 1% BSA with several strokes in a Teﬂon-glass homogeniser at 700 rpm.
Nuclei and ﬂy body debris were pelleted by two centrifugation steps at 1000 × g for
5 min, 4 °C and the supernatant centrifuged for 10 min at 3000 × g, 4 °C. After a
wash in 5 mL STE buffer+ 1% BSA, the mitochondrial pellet was resuspended in
STE buffer (without BSA) and centrifuged at 7000 × g, 4 °C for 10 min. Mito-
chondria pellet was resuspended in 1 mL of STE buffer for protein quantiﬁcation
using the Pierce BCA method (Thermo Fisher Scientiﬁc, RRID:SCR_008452).
Sample preparation and Blue-Native PAGE were performed as follows: 800 μg of
pelleted mitochondria were resuspended in 1.5 M aminocaproic acid, 50 mM Bis-
Tris·HCl pH 7 to a ﬁnal concentration of 10 mgmL−1 and solubilised with 4 mg
digitonin per mg of protein. After 5 min incubation on ice, mitochondria were
centrifuged at maximum speed (20,000 × g) at 4 °C for 30 min. Supernatant was
mixed with 10 μL of Blue-Native Sample Buffer [750 mM aminocaproic acid, 50
mM Bis-Tris·HCl pH 7, 0.5 mM EDTA, 5% Serva Blue G] and 10 μL of extracts
loaded for Blue-Native Gel Electrophoresis on a pre-cast NativePAGE 3–12% Bis-
Tris gel (Life Technologies, RRID:SCR_008817). For in-gel complex activity, the
BN-PAGE gel was incubated for several hours at room temperature in complex-
speciﬁc solutions. For complex-I activity: 5 mM Tris–HCl, pH 7.4, 0.1 mg mL−1
NADH, and 2.5 mgmL−1 NTB (NitroTetrazolium Blue); for complex-II activity:
5 mM Tris–HCl, pH 7.4, 0.2 mM phenazine methasulfate, 20 mM sodium succinate
and 2.5 mgmL−1 NTB; for complex-IV: 50 mM sodium phosphate buffer, pH 7.4,
0.5 mg mL−1 DAB (3,3′-diaminobenzidine tetrahydrochloride), 24 UmL−1 cata-
lase, 10 mgmL−1 cytochrome c (horse heart < 95% purity), 75 mgmL−1 sucrose.
Subcellular fractionation. 200–250 adult ﬂies (both males and females) were
homogenised in 4 mL of cold 250-STM buffer [250 mM sucrose, 50 mM Tris·HCl
pH 7.4, 5 mM MgCl2] freshly supplied with 1 mM DTT, 1 mM PMSF, 25 μg mL−1
Spermine and 25 μg mL−1 Spermidine. The homogenate was then sieved through a
70 μm cell strainer (Corning BV) to remove gross body parts (legs and wings). An
aliquot of the decanted homogenate was collected as total fraction, and the rest
centrifuged at 800 × g for 15 min at 4 °C using a swing-out rotor. Supernatant was
stored on ice for further isolation of mitochondria and cytosolic fraction. Nuclei-
containing pellet was washed with lysis buffer and nuclei isolated at the bottom of a
2M-STMDPS [2M sucrose, 50 mM Tris·HCl pH 7.4, 5 mM MgCl2, 1 mM DTT,
1 mM PMSF, 25 μg mL−1 Spermine and 25 μg mL−1 Spermidine] cushion after
ultracentrifugation at 80,000 × g for 30 min at 4 °C (Beckman Coulter, RRID:
SCR_008940 ultracentrifuge). The nuclear pellet was lysed with 50 μL of NE buffer
[20 mM HEPES pH 7.9, 0.5 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 20% glycerol]
for at least 30 min at 4 °C and nuclear fraction stored at −80 °C. Mitochondria
were separated from cytosol by centrifugation of the nuclei-free homogenate at
6000 × g for 15 min using a swing-out rotor. After a quick wash of the pellet,
mitochondria proteins were extracted in 70 μL of HDP buffer [10 mM HEPES pH
7.9, 1 mM DTT, 1 mM PMSF] and stored at −80 °C. Supernatant from the
mitochondrial centrifugation was processed to obtain a clean cytosolic fraction by
ultracentrifugation at 100,000 × g for 1 h at 4 °C (Beckman Coulter, RRID:
SCR_008940 ultracentrifuge) (pellet discarded) and stored at −80 °C. Samples
from each fraction were quantiﬁed using Pierce BCA assay (Thermo Fisher Sci-
entiﬁc, RRID:SCR_008452) and 15 μg of total protein lysate were loaded on a
4–20% gel (Bio-Rad Laboratories, RRID:SCR_008426), resolved via SDS-PAGE
(Bio-Rad Laboratories, RRID:SCR_008426) and blotted to a nitrocelullose mem-
brane. Histone-H3 immuno-reactivity was used to mark the nuclear fraction,
ATP5A was used as a mitochondrial marker and GAPDH as a cytoplasmic marker.
Immunoblotting. For APOBEC1 expression analysis, protein samples were isolated
from whole adult ﬂies. Flies were homogenized in RIPA lysis buffer [50 mM
Tris·HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% SDS] with 1 mM
PMSF and protease inhibitor mixture (Roche, RRID:SCR_001326). Protein extracts
were quantiﬁed using the Pierce BCA assay (Thermo Fisher Scientiﬁc, RRID:
SCR_008452). Typically, 30 µg of protein were resolved by SDS-PAGE (Bio-Rad
Laboratories, RRID:SCR_008426) and transferred onto nitrocellulose membrane
using a semi-dry Transblot apparatus (Bio-Rad Laboratories, RRID:SCR_008426)
according to the manufacturer’s instructions. Membranes were blocked with 5%
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skimmed milk in TBST [Tris-buffered saline, 0.1% Tween 20] for 1 h at RT and
incubated with primary antibody overnight at 4 °C. After several washes in TBST,
appropriate horseradish peroxidase-conjugated secondary antibodies were incu-
bated for 1 h at RT. Detection was achieved with ECL-Plus detection kit (GE
Healthcare, RRID:SCR_000004) using a ChemiDoc XRS+molecular imager (Bio-
Rad Laboratories, RRID:SCR_008426) and analysed by Image Lab Software (Image
Lab Software, RRID:SCR_014210).
For immunoblotting of native OXPHOS complexes, Blue Native gels of
mitochondria-enriched samples were transferred onto PVDF membranes via wet
transfer (Bio-Rad Laboratories, RRID:SCR_008426) following manufacturer’s
instructions. Membranes were blocked and incubated with primary and secondary
antibodies as described above. Detection was achieved with ECL-Plus detection kit
(GE Healthcare, RRID:SCR_000004) using an Amersham Imager 600 imaging
device.
Antibodies and dyes. For immunoﬂuorescence experiments, the following pri-
mary antibodies were used: mouse anti-ATP5A (Abcam Cat# ab14748, RRID:
AB_301447; 1:500), rabbit anti-HA (Abcam Cat# ab9110, RRID:AB_307019;
1:500). Secondary antibodies were: anti-rabbit AF647 (Thermo Fisher Scientiﬁc
Cat# A-21244, RRID:AB_2535812; 1:200), anti-mouse AF488 (Thermo Fisher
Scientiﬁc Cat# A-11001, RRID:AB_2534069; 1:200).
For immunoblot experiments, the following antibodies were used: mouse anti-
Actin (Millipore Cat# MAB1501, RRID:AB_2223041; 1:5,000), mouse anti-
APOBEC1 (E-2) (Santa Cruz Biotechnology Cat# sc-166508, RRID:AB_2057252;
1:1,000), mouse anti-ATP5A (Abcam Cat# ab14748, RRID:AB_301447; 1:20,000),
mouse anti-GAPDH (GeneTex Cat# GTX627408, RRID:AB_11174761; 1:2,000),
rabbit anti-HA (Abcam Cat# ab9110, RRID:AB_307019; 1:2,000), rabbit anti-
HistoneH3 (Abcam Cat# ab1791, RRID:AB_302613; 1:1,000), mouse anti-MTCO3
(Abcam Cat# ab110259, RRID:AB_10859925; 1:600), mouse anti-NDUFS3 (Abcam
Cat# ab14711, RRID:AB_301429; 1:600), rabbit anti-Porin (Millipore Cat# PC548,
RRID:AB_2257155; 1:5,000), mouse anti-Tubulin (Sigma-Aldrich Cat# T6793,
RRID:AB_477585, 1:5,000), mouse anti-UQCRFS1 (Abcam Cat# ab14746, RRID:
AB_301445; 1:600). Horseradish peroxidase-conjugated secondary antibodies: anti-
mouse (Abcam Cat# ab6789, RRID:AB_955439; 1:5,000 to 1:20,000), anti-rabbit
(Thermo Fisher Scientiﬁc Cat# G-21234, RRID:AB_2536530; 1:3,000 to 1:5,000).
Statistical analysis. Data are reported as mean ± SD, mean ± SEM or mean ± 95%
CI as indicated in ﬁgure legends. For statistical analyses of lifespan experiments, a
log-rank (Mantel–Cox) test was used. For behavioural analyses, a Kruskal–Wallis
nonparametric test with Dunn’s post-hoc correction for multiple comparisons was
used. Signiﬁcance in mtDNA copy number by qPCR and mitochondrial transcripts
analyses was determined by a two-way ANOVA test with Tukey’s post-hoc cor-
rection for multiple comparisons. Signiﬁcance in Southern blot quantiﬁcation and
Oroboros (respirometry) experiments was determined by a one-way ANOVA test
with Sidak’s post-hoc correction for multiple comparisons. Signiﬁcance levels are
indicated in the ﬁgure legends. Unless speciﬁcally indicated, no signiﬁcant differ-
ence was found between a sample and any other sample in the analysis. Statistical
analyses were performed using GraphPad Prism 7 software (GraphPad Prism,
RRID:SCR_002798).
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